2,047 reports of this reaction
4.3% of all SUMATRIPTAN SUCCINATE reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for SUMATRIPTAN SUCCINATE, manufactured by Tonix Medicines, Inc.. There are 2,047 FDA adverse event reports linking SUMATRIPTAN SUCCINATE to HEADACHE. This represents approximately 4.3% of all 47,922 adverse event reports for this drug.
Patients taking SUMATRIPTAN SUCCINATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among SUMATRIPTAN SUCCINATE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for SUMATRIPTAN SUCCINATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 2,047 FDA reports for SUMATRIPTAN SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.3% of all adverse event reports for SUMATRIPTAN SUCCINATE, making it one of the most commonly reported side effect.
If you experience headache while taking SUMATRIPTAN SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.